Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.
MONDAY, June 19, 2023 (HealthDay News) Pancreatic cancer is often considered a death sentence, typically aggressive and usually caught late, but there is one type of pancreatic cancer that
Patients with locally advanced rectal cancer treated with FOLFOX before surgery had similar outcomes and side effect profiles to those treated with presurgical pelvic chemoradiation.
Neoadjuvant treatment with fluorouracil, leucovorin, and oxaliplatin proved to be as effective as pelvic chemoradiation with fewer adverse effects in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery.
Sara Schottenstein Foundation Announces Launch; Dedicated To Ending Gastric Cancer
Foundation honors wife, mother and attorney Sara Schottenstein
News provided by
Share this article
Share this article
TIBURON, Calif., Jan. 21, 2021 /PRNewswire/ The Sara Schottenstein Foundation, a science-focused organization dedicated to ending gastric cancer, today announced its launch and new website, http://www.saraschottensteinfoundation.org/. Founded by Jeff Schottenstein, a wealth management professional in San Francisco, the Sara Schottenstein Foundation supports innovative gastric cancer research, raises awareness, and champions patients and their caregivers. It also honors Sara Schottenstein (1967-2016), Jeff s late wife, and her inspirational life and efforts to overcome gastric cancer.